Go to Samples
Eli Lilly and Co.Jaypirca100mg x 30 per package
Indications and Usage
INDICATIONS AND USAGE
JAYPIRCA ® is a kinase inhibitor indicated for the treatment of:
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. . This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. .
Mantle Cell Lymphoma
JAYPIRCA ® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate [see Clinical Studies ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
FAQsAll you need to know to order samples
Due to manufacturer restrictions, there are some limitations on the quantities of samples that can be included in each order. We're working on new functionality to let your practice place larger, batch orders.